NNC2215

Last updated

NNC2215 is a bioengineered glucose-sensitive insulin. The drug is designed by a team of Novo Nordisk researchers. [1]

Contents

NNC2215 can sense the glucose concentration presence in blood, through incorporation of a glucose binding molecule developed in the University of Bristol. [2] The protein's sensitivity is reduced when low concentration of glucose, thus reducing the risk of hypoglycemia. [3] In addition, it can effectively cover the risk of fluctuations of blood sugar levels.

The study was published on scientific journal Nature on October 16, 2024. [4] This study demonstrated the ability of protein engineering in future medicine and a major advancement in treatment capabilities.

Background

A glucose sensitive treatment method for diabetes has long been pursued by researchers since 1979. [5] Such a platform is expected to solve the problem of fluctuations of blood sugar levels. For diabetic patients, skipping a single meal can lead to hypoglycemia, a common complication which can lead to loss of consciousness or seizures. [6]

There have been several attempts to create such a medicine, with various levels of success. [7] [8]

See also

References

  1. ↑ PhD, Jonathan D. Grinstein (2024-10-21). "Novo Nordisk Researchers Engineer Glucose-Sensitive Insulin Switch". Inside Precision Medicine. Retrieved 2025-01-01.
  2. ↑ Tromans, Robert A.; Carter, Tom S.; Chabanne, Laurent; Crump, Matthew P.; Li, Hongyu; Matlock, Johnathan V.; Orchard, Michael G.; Davis, Anthony P. (2019). "A biomimetic receptor for glucose". Nature Chemistry. 11 (1): 52–56. doi:10.1038/s41557-018-0155-z. ISSN   1755-4349.
  3. ↑ Kwon, Diana (2024-10-16). "'Smart' insulin prevents diabetic highs — and deadly lows" . Nature. doi:10.1038/d41586-024-03357-7. PMID   39414970.
  4. ↑ Hoeg-Jensen, Thomas; Kruse, Thomas; Brand, Christian L.; Sturis, Jeppe; Fledelius, Christian; Nielsen, Peter K.; Nishimura, Erica; Madsen, Alice R.; Lykke, Lennart; Halskov, Kim S.; Koščová, Simona; Kotek, Vladislav; Davis, Anthony P.; Tromans, Robert A.; Tomsett, Michael (16 October 2024). "Glucose-sensitive insulin with attenuation of hypoglycaemia". Nature. 634 (8035): 944–951. Bibcode:2024Natur.634..944H. doi:10.1038/s41586-024-08042-3. ISSN   1476-4687. PMC   11499270 . PMID   39415004.
  5. ↑ Brownlee, Michael; Cerami, Anthony (1979-12-07). "A Glucose-Controlled Insulin-Delivery System: Semisynthetic Insulin Bound to Lectin" . Science. 206 (4423): 1190–1191. Bibcode:1979Sci...206.1190B. doi:10.1126/science.505005. PMID   505005.
  6. ↑ "Low Blood Glucose (Hypoglycemia) - NIDDK". National Institute of Diabetes and Digestive and Kidney Diseases. Retrieved 2025-01-01.
  7. ↑ Jarosinski, Mark A; Chen, Yen-Shan; Varas, Nicolás; Dhayalan, Balamurugan; Chatterjee, Deepak; Weiss, Michael A (2022-04-01). "New Horizons: Next-Generation Insulin Analogues: Structural Principles and Clinical Goals". The Journal of Clinical Endocrinology & Metabolism. 107 (4): 909–928. doi:10.1210/clinem/dgab849. ISSN   0021-972X. PMC   8947325 . PMID   34850005.
  8. ↑ Liu, Yun; Wang, Shiqi; Wang, Zejun; Yu, Jicheng; Wang, Jinqiang; Buse, John B.; Gu, Zhen (2024-06-10). "Recent Progress in Glucose-Responsive Insulin" . Diabetes. 73 (9): 1377–1388. doi:10.2337/dbi23-0028. ISSN   0012-1797. PMID   38857114.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.